Phase 2
N=39
Evaluation of Cortisol Resistance in Young Sedentary and Endurance-Trained Men
Cortisol Resistance · Negative Feedback · ACTH · Mineralcorticoid · Glucocorticoid
Bottom Line
View on ClinicalTrials.gov: NCT01294319 ↗Enrolled (actual)
39
Serious AEs
0.0%
Results posted
Nov 2017
Primary outcome: Primary: Proportion of Suppressors After Dexamethasone — 0; 1 Participants — p=0.4872
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Mifepristone (Drug); Placebo (Drug); Spironolactone (Drug); Combined (Drug); Dexamethasone (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- Male
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Primary completion
- Aug 2016
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Proportion of Suppressors After Dexamethasone |
0; 1 | 0.4872 |
| SECONDARY Post-dexamethasone Cortisol Level |
11.98; 9.98 | 0.2786 |
Summary
This study proposes to examine multiple aspects of the hypothalamic-pituitary-adrenal axis in younger endurance trained and sedentary men, and in older sedentary men.
Eligibility Criteria
- INCLUSION CRITERIA:
Men aged 18 to 30 years of age are required for the young endurance trained and sedentary groups; men aged 65-80 years for the older study group, who will meet criteria for sedentary men below. Women and children are excluded to enhance homogeneity of responses and avoid the influence of menstrual cyclicity on the HPA axis.
Sedentary:
- Less than one hour physical activity per week for three years
- No change in exercise anticipated for 6 weeks
Trained:
- Greater than 45km (28 miles) running per week for at least 3 months
- No change in exercise anticipated for 6 weeks
For all participants:
- All races
- Sleep-wake cycle with sleeping at night, wakening between 5 and 8 AM
- BMI between 18 and 25 kg/M2
- Normal TSH and free T4
EXCLUSION CRITERIA
For all participants:
- Sleep disorders as assessed by sleep apnea questionnaire
- Smoking
- No more than 2 servings of alcohol daily
- Medications known to affect the HPA axis or steroid metabolism, including narcotics, Glucocorticoids, megace or CYP3A4 modulators
- History of psychiatric or endocrine disorders
- Marijuana or other illicit drug use
- Recent appendicular or skeletal injury
- Uncontrolled hypertension
- Chronic pain requiring daily medication
- Current treatment with medications related to mineralocorticoid function such as potassium, ACE-inhibitors, ARBs, diuretics, spironolactone
- Frailty score of 4-7 on the Canadian Study of Health and Aging frailty scale (Rockman 2005)
- Overtraining syndrome will be an exclusion and will be assessed by questionnaire
- Abnormal creatinine level (greater than 1.2 mg/dl)
- Liver function tests greater than two fold normal
- Benzodiazepine use
Data sourced from ClinicalTrials.gov (NCT01294319). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.